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Prostate cancer gene expression marker 1 (PCGEM1) is a long non-coding RNA (lncRNA) overexpressed in prostate
cancer (PCa) cells that promotes PCa initiation and progression, and protects against chemotherapy-induced apoptosis.
The microRNA miR-145 functions as a tumor suppressor in PCa. We speculate that reciprocal regulation of PCGEM1 and
miR-145 promote proliferation of LNCaP prostate cancer cells. To test this hypothesis, the interaction between PCGEM1 and
miR-145 was examined using a luciferase reporter assay. Expression levels were selectively altered in LNCaP cells and
noncancerous RWPE-1 prostate cells by transfection of miR-145 or small interfering RNA sequences against (siRNA)
PCGEM1. Relative expression levels were detected by RT-PCR, tumor cell growth and early apoptosis by the MTT assay
and flow cytometry, respectively, and tumor cell migration and invasion properties by transwell assays. The effect of siRNA
PCGEM1 and miR-145 transfection on prostate cancer growth in vivo was examined in the (nu/nu) mouse model. PCGEM1
and miR-145 exhibited reciprocal regulation; downregulation of PCGEM1 expression in LNCaP cells increased expression
of miR-145, while overexpression of miR-145 decreased PCGEM1 expression. Transfection of the miR-145 expression vector
and siRNA PCGEM1 inhibited tumor cell proliferation, migration, and invasion, and induced early apoptosis both in vitro.
In contrast, there was no effect on RWPE-1 cells. We demonstrate a reciprocal negative control relationship between
PCGEM1 and miR-145 that regulates both LNCaP cell proliferation and nu/nu PCa tumor growth. The results also identify
PCGEM1 and associated regulators as possible targets for PCa therapy.
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Long non-coding RNAs (lncRNAs) are untranslated
transcripts longer than 200 nucleotides baring many of
the structural characteristics of mRNAs, including a
polyA tail, 5′-capping, and a promoter structure, but no
conserved open reading frame [1-6]. Many lncRNAs are
expressed at specific times and in specific tissues during
development, and exhibit a variety of slicing patterns. It
has been proposed that lncRNAs are involved in the epi-
genetic regulation of coding genes, and thus exert a power-
ful effect on a number of physiological and pathological* Correspondence: lyg_py@126.com
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unless otherwise stated.processes, including the pathogenesis of many human can-
cers [7-11].
MicroRNAs (miRs) are small noncoding RNAs usually
20–22 nucleotides long. To date, close to 1000 human
miRs have been identified. Collectively, miRs are thought
to regulate more than 50% of all human genes by binding
to mRNA sequences and repressing expression, either by
inhibiting translation or promoting RNA degradation
[12-17].
Given the structural similarly with mRNAs, lncRNAs
may be another important member of the non-coding
RNA family [18]. The interaction between lncRNAs and
miRs has been linked to the invasion and metastasis of
tumors [19]. For example, the miR-29a epigenetically
modulated expression of the lncRNA MEG3 in hepato-
cellular carcinoma (HCC) through promoter hypermethy-
lation [20]. Loss of miR-31 expression in triple-negativeThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
He et al. Journal of Experimental & Clinical Cancer Research 2014, 33:72 Page 2 of 10
http://www.jeccr.com/content/33/1/72breast cancer (TNBC) lines is attributed to hypermethyla-
tion of its promoter-associated CpG islan. MicroRNA-31
anchors the novel lncRNA LOC554202 and adjusts its
transcriptional activity [21]. Moreover, the lncRNA HULC
can inhibit the expression of the tumorigenic miR-372 [22].
Prostate cancer gene expression marker 1 (PCGEM1)
is part of a novel class of androgen-regulated lncRNAs
[23]. Overexpression in prostate cancer (PCa)-derived
LNCaP cells promotes proliferation and a dramatic in-
crease in colony formation [24,25]. Many miRs function
as oncogenes or tumor suppressors in human cancers
[26-32]. Downregulation of miR-145 has been reported
in PCa, suggesting that miR-145 functions as a tumor
suppressor [33]. Using the biology information software
RegRNA (http://regrna.mbc.nctu.edu.tw/), we predicted
that 48 distinct miRs bind to PCGEM1. Further online
comprehensive analysis (http://cbio.mskcc.org/cancerge-
nomics/prostate/data/) indicates that 96 miRs are associ-
ated with PCa. Clustering intersection analysis also
linked miR-145 with PCa. Significantly, miR-145 has a
binding site for lncRNA; thus, reciprocal regulation of
PCGEM1 and miR-145 may promote or suppress PCa
cell proliferation [34]. In this study, we explored possible
mutual regulation of PCGEM1 and miR-145 expression
in prostate cancer and the impact on PCa cell prolifera-
tion and invasive capacity.
Materials and methods
Materials
Non-cancerous RWPE-1 cells, HEK293T cells and LNCaP
cells were purchased from the Shanghai Institute of Cell
Biology (Shanghai, China). RPMI 1640 medium, fetal bo-
vine serum (FBS), and Lipofectamine 2000 were obtained
from Invitrogen (Carlsbad, CA, USA). The restriction en-
zymes NotI and XhoI, T4 DNA ligase, and reagents for
RT-PCR were purchased from TaKaRa (Takara BioInc,
Shiga, Japan). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT), annexin-V-FITC, and propi-
dium iodide (PI) were purchased from Sigma Chemical
(USA), and negative control sequences and negative con-
trol inhibitor sequences were purchased from Ruibo Com-
pany (Shanghai, China).
Design and construction of eukaryotic expression vector
for hsa-miR-145
The mature hsa-miR-145 sequence (5′-GUCCAGUUU
CCCAGGAAUCCCU-3′) is available from the miRNA
Registry (MIMATOOOO437). To prevent formation of
a termination signal, TTGGCCACTGACT was selected
as the region in a miR expression vector template. The
sequence TGCT was added to the 5′ positive-sense
strand template of the miR expression vector and GTCC
to the 5′ antisense strand template. Further, a nonspecific
sequence was designed and sent to Shanghai GenePharmaCo, Ltd. for synthesis. The assay was according to previ-
ously described [35]. The eukaryotic expression vector
plasmid targeting hsa-miR-145 was named pmiR-145.Design and synthesis of siRNA
siRNAs are methylated 21 bp double-stranded RNA oli-
gonucleotides. It uses gene-specific targets for RNAi
analysis and reports up to 10 top scoring siRNA targets.
The freeze-dried siRNAs were dissolved in RNase-free
water and stored as aliquots at −20°C. The siRNA se-
quence of PCGEM1 (sense: 5′-GCCCUACCUAUGAUU
UCAUAU-3′, antisense: 5′-AUAUGAAAUCAUAGGUA
GGGC-3′) and negative control sequence (sense: 5′-UU
CUCCGAACGUGUCACGUUUC-3′ antisense: 5′-GAAA
CGUGACACGUUCGGAGAA-3′) were synthesized by
Shanghai GenePharma (Shanghai, China).Grouping and cell transfection
The experimental culture groups included 1) untrans-
fected LNCaP and RWPE-1 cells (control groups), 2)
cells transfected with pmiR-145 or miR-145 mimics
(1.6 μg/ml and 50 nM, respectively), 3) cells transfected
with the scrambled nucleotide sequence and empty vec-
tor (negative control or NC groups, 50 nM), 4) cells
transfected with a miRNA inhibitor (NI group, 100 nM),
5) a negative control for NI (NCI group, 50 nM), 6) cells
transfected with siRNA PCGEM1 sequence (siRNA
PCGEM1 group, 50 nM). Cells in log phase growth were
seeded on 6-well culture plates (2 × 105 cells/well) and
transfected when the cell fusion rate reached 70%. The
DNA Lipofectamine 2000 or RNA Lipofectamine 2000
compound was added according to the manufacturer’s
instructions (Invitrogen). After 6 h, the transfection
medium was discarded. Cells were washed with serum-
free RPMI 1640 and then cultured in RPMI 1640 supple-
mented with 10% FBS.Luciferase reporter assay
The whole mRNA sequences of the PCGEM1 gene were
obtained by PCR amplification and cloned separately into
multiple cloning sites of the psi-CHECKTM-2 luciferase
miRNA expression reporter vector. HEK293T cells were
transfected with miR-145 mimic, miR-145 inhibitor, a
control miRNA, a miRNA inhibitor control, or empty
plasmid using Lipofectamine 2000 according to the manu-
facturer’s instructions. Nucleotide-substitution mutation
analysis was carried out using direct oligomer synthesis of
PCGEM1 sequences. All constructs were verified by se-
quencing. Luciferase activity was measured using the dual
luciferase reporter assay system kit (Promega Co, Madison,
WI, USA) according to the manufacturer’s instructions on
a Tecan M200 luminescence reader.
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Total RNA samples were extracted using Trizol (Invitro-
gen, CA) according to the manufacturer’s instructions.
Real-time quantitative PCR analysis was performed using
an Applied Biosystems 7500 Real-Time PCR Systems
(Applied Biosystems, Foster City, CA). The expression
level of 18S was used as an internal control for mRNAs,
and U6 level as an internal control for miRNAs. Primers
used in quantitative real-time PCR analysis were: U6 (for-
ward: 5′-CTCGCTTCGGCAGCACA -3′, reverse: 5′-
AACGCTTCACGAATTTGCGT-3′); 18S (forward: 5′-CC
TGGATACCGCAGCTAGGA-3′, reverse: 5′-GCGGCG




TGGTGTCGTGGA-3′); PCGEM1 (forward: 5′-CACG
TGGAGGACTAAGGGTA-3′, reverse: 5′-TTGCAACA
AGGGCATTTCAG-3′); The expression level was cal-
culated using CT and 2-ΔΔCt.
MTT assay
The viability of LNCaP and RWPE-1 cells was deter-
mined by MTT assay. Briefly, cells at 5 × 104/ml were
transfected with siRNA PCGEM1 (siRNA PCGEM1
groups, 50 nM), empty plasmid and scramble sequence
(negative control group, 1.6 μg/ml), or pmiR-145 (pmiR-
145 group, 1.6 μg/ml) in the presence of Lipofectamine
2000 and serum-free RPMI 1640 media for 6 h. Cells
were plated in 96-well plates in medium containing 10%
FBS for another 24, 48, or 72 h. MTT stock solution
(20 μl, 5 mg ⁄ml) was added to each well for a final MTT
concentration of 0.45 mg⁄ml and the plate was incubated
for 4 h at 37°C. Media was then removed and dimethyl-
sulfoxide (DMSO) (150 μl added to dissolve the blue for-
mazan crystals (the product of MTT conversion by
viable cells) at room temperature for 30 min. The rela-
tive change in viable cell number was estimated by ab-
sorbance at 570 nm on a Bio-Rad microtiter plate reader
(Hercules, CA, USA).
Flow cytometry assay
LNCaP and RWPE-1 cells were seeded at 1.0 × 106/ml in
24-well plates (Costar) and transfected in 500 μl media/
well siRNA PCGEM1 (siRNA PCGEM1 groups, 50 nM),
empty plasmid and scramble sequence (negative control
group, 1.6 μg/ml), or pmiR-145 (pmiR-145 group,
1.6 μg/ml) by Lipofectamine 2000 reagent (Invitrogen)
in serum-free RPMI 1640 for 6 h. After transfection,
500 μl of the appropriate growth medium containing
20% FBS were added to each well. Cells were incubated
for another 48 h then harvested, washed twice with PBS,
fixed with 70% ethanol, and treated with RNase A
(1 mg/ml). Finally, the cells were double-stained withFITC-conjugated annexin-V and propidium iodide (PI)
solution (50 μg/ml). For each sample, data from approxi-
mately 10000 cells were recorded in the list mode on
logarithmic scales. Apoptosis and necrosis were analyzed
by quadrant statistics on double negative, annexin-V-
positive/PI-negative, annexin-V-negative/PI-positive, and
double-positive cells.Migration and invasion assay
Cells were transfected with siRNA PCGEM1 (siRNA
PCGEM1 groups, 50 nM), empty plasmid and scramble
sequence (negative control group, 1.6 μg/ml), or pmiR-
145 (pmiR-145 group, 1.6 μg/ml) by Lipofectamine 2000
reagent in serum-free RPMI 1640 for 6 h. One day after
transfection, 1 × 105 cells were collected, resuspend in
100 μl basal medium, and transferred to the transwell
chamber. A 600 μl volume of complete medium was
added to the well and the chamber inserted. Plates were
incubated at 37°C for 48 h. Remaining cells were swabbed
from the top transwell membrane filter and the chamber
submerged in 4% paraformaldehyde for 20 min. Cells in
the well were stained with crystal violet for 10 min,
washed in PBS buffer, then counted by light microscope
to determine transwell migration.
The transwell assay was performed as above except
with Matrigel in the wells of 24-well plates. The Matrigel
was first incubated in pre-chilled basal medium (40 μl)
at 37°C for 2 h. The excess medium was discarded,
100 μl basal medium added to the well with the Matrigel
and 600 μl to the chamber, following by incubation at
37°C overnight. Transfected cells (1 × 105) were resus-
pend in 100 μl basal medium and transfer to the trans-
well chamber. Then, 600 μl complete medium was
added to the well and the chamber inserted. The plates
were incubated at 37°C for 24 or 48 h. Cells were stained
with crystal violet for 10 min, washed with the PBS and
counted using an inverted microscope.In vivo treatment
BalB/c (nu/nu) mice from the Animal Center of
Guangzhou Province (Guangdong, China) received sub-
cutaneous injections of 2 × 106 LNCaP cells into each
axilla area. When xenograft tumors became palpable
(about 0.1 mm3), mice were randomly divided into the
control group receiving PBS injection (100 μl), siRNA
PCGEM1 (500 nM), negative control (plasmid, scram-
ble sequence 16 μg), PmiR-145 (16 μg), with 6 mice
each group. There was no difference in baseline tumor
size between the groups. Tumor volume was calculated
every 3 days according to the formula v = ab2π/6, where
“a” is the maximum tumor diameter and “b” the mini-
mum diameter. After treatment for 20 d, mice were eu-
thanized and tumors were dissected and weighed.
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All results are the averages of at least three independent
experiments from separately treated and transfected cul-
tures. Data are expressed as the mean ± SD. Statistical
comparisons were made by one-way analysis of variance
(ANOVA). P < 0.05 was considered to indicate a statisti-
cally significant difference.
Results
miR-145 regulates PCGEM1 expression by binding to the
PCGEM1
ReRNA, an lncRNA target miR prediction software, pre-
dicted miR-145 binding sites at 983 bp and 1004 bp in
the PCGEM1 (Figure 1C). The full-length sequence of
PCGEM1 (1643 bp) was cloned downstream of the
luciferase gene in the psiCHECK carrier to construct
the psiCHECK-2-PCGEM1 carrier. Co-transfection of
HEK293T cells with miR-145 mimics was performed
to detect the binding site on the PCGEM1 (983–1004 bp).
The co-transfection of HEK293T cells with miR-145
mimics and psiCHECK-2-PCGEM1 also significantly
inhibited luciferase activity (P <0.05) (Figure 1A);
however, co-transfection of HEK293T cells with miR-
145 mimics and empty psiCHECK-2 had little effect
on the activity of luciferase (P > 0.05) (Figure 1B). We
concluded that miR-145 can regulate the expression
of PCGEM1 by directly binding to target sites within
the PCGEM1 sequence.Figure 1 The interaction between miR-145 and PCGEM1 was detected
transfected cloned PCGEM1 (P△ < 0.05) vs control and NC. B: The luciferase
IN, NC, NCI group. C: The target sequence for miR-145 at 1: Control group;The miR-145 and PCGEM1 expression in in the LNCaP cells
exhibited reciprocal regulation
To examine possible mutual regulation of PCGEM1 and
miR-145, we designed a small interfering RNA sequences
to knockdown PCGEM1 expression and detected the ex-
pression levels of miR-145. Alternatively, we transfected
PmiR-145 into LNCaP cells and then detected the expres-
sion levels of PCGEM1. Transfection of the siRNA
PCGEM1 downregulated expression of PCGEM1 and re-
sulted in a significant increase in miR-145 expression com-
pared to the NC group and control group (both P < 0.05)
(Figure 2).siRNA-mediated PCGEM1 knockdown and miR-145
overexpression inhibited LNCaP proliferation
To examined the effect of siRNA-mediated PCGEM1
knockdown and concomitant overexpression of miR-145
on PCa cell proliferation, normal prostate cells (RWPE–1)
and LNCaP cells were transfected as above and cell num-
bers estimated by MTT after 24, 48, 72 h. Indeed, both
siRNA PCGEM1 and PmiR-145 transfection groups ex-
hibited a significant reduction in LNCaP cell proliferation,
while transfection with empty vector and scrambled se-
quences (negative control group) had no effect compared
to untransfected controls (Figure 3A). In contrast, prolif-
eration of RWPE-1 cell was not changed significantly,
even after 72 h (Figure 3B).by sensor reporter. A: Comparison of luciferase activity of plasmid
activity comparison of empty psiCHECK-2 (P* > 0.05) vs control and NC,
2: miR-145 mimics group; 3: inhibitor group; 4: NC group; 5: NCI group.
Figure 2 The relative expression levels of PCGEM1 and miR-145. A: The PCGEM1 mRNA expression levels were determined by Real time RT-PCR,
P△* < 0.05 vs control and NC group. B: The miR-145 expression levels determined by Real time RT-PCR, P△* < 0.05 vs control and NC group. 1: Control
group; 2: Negative group: 3: siRNA PCGEM1 group. 4. PmiR-145 group.
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overexpression induced early apoptosis of LNCaP cell
Cell apoptosis of the above transfection groups was de-
tected by flow cytometry using annexin-V/PI double
staining. In total, 25.16% of PCGEM1 knockdown and
23.6% of miR-145-overexpressing LNCaP cells were in
early apoptosis (Figure 4A, C), compared to only 0.63%
and 0.82% of RWPE-1 cells, respectively, in these same
transfection groups (Figure 4B, D).
siRNA-mediated PCGEM1 knockdown and miR-145
overexpression decreased LNCaP cell migration and
invasion
Transwell migration assays revealed that PCGEM1 knock-
down led to a mean 46 ± 8.6% decrease in LNCaP cell mi-
gration, and miR-145 overexpression to a mean 36 ± 7.8%
decrease (Figure 5A), while these treatments had no effect
on REWP-1 cell migration (Figure 5B). The effect of
siRNA PCGEM1/PmiR-145 on LNCaP cell invasion wasFigure 3 The viability of cells determind by MTT assay. LNCaP cells afte
10% FBS for another 24, 48, 72 hour. Cell viability was assessed by MTT assays.
represented. A: The inhibitory rates of LNCaP cells, P△* < 0.05 vs NC group. B: Tevaluated using Matrigel-coated Transwell invasion assays.
siRNA PCGEM1 led to a mean 52 ± 6.6% decrease in
LNCaP cell invasion and pmiR-145 led to a mean 59 ±
6.3% decrease in LNCaP cell invasion (Figure 5C). siRNA
PCGEM1 and PmiR-145 have no effects on RWPE-1 cell
invasion (Figure 5D).
siRNA-mediated PCGEM1 knockdown and miR-145
overexpression inhibits progression of tumor
xenografts
LNCaP tumor xenografts were established in Athymic
nude mice to evaluate the effects of siRNA PCGEM1 or
pmiR-145 on prostate cancer growth in vivo. Compared to
the untreated animals, application of siRNA PCGEM1 or
pmiR-145 significantly diminished the tumor volume,
whereas negtive control group had no effect (Figure 6).
No body weight loss or diarrhea was observed and all ani-
mals (treated as well as non-treated) survived. The results
shows that shows that reduce the expression of PCGEM1r transfection, the cells were plated in 96-well plates in medium containing
Mean values of three independent experiments with standard errors are
he inhibitory rates of RWPE-1cells, P△* > 0.05 vs NC group.
Figure 4 The cell early apoptotis rate was detecte by flow cytometry. LNCaP and RWPE-1 cells cells were serum-starved for 6 h and then
transfected with siRNA PCGEM1 or PmiR-145. After 48 h cells were collected and fixed in paraformaldehyde and ethanol overnight. Cells were stained
by propidium iodide (PI) and with FITC-conjugated AnnexinV, analyzed by flow cytometry with a BD FACScalibur (BD Bioscience, Heidelberg, Germany).
Mean values of three independent experiments with standard errors are represented. A: Representative Annexin V/PI double staining LNCaP cells.
B: Representative Annexin V/PI double staining RWPE-1 cells. C: Comparison of the percentage of early apoptosis in LNCaP cells, P△* < 0.05 vs control
and NC group. D: Comparison of the percentage of early apoptosis in RWPE-1 cells, P△* > 0.05 vs control and NC group. 1: Control group; 2: Negative
group: 3: siRNA PCGEM1 group. 4. PmiR-145 group.
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cancer growth in vivo.
Discussion
Long non-coding RNAs (lncRNAs) are a new class of
regulatory RNA [36]. These mRNA-like molecules,
which lack significant protein-coding capacity, wereonce thought to be a part of the genomic “dark matter”,
but recent studies have implicated lncRNAs in a wide
range of biological functions through poorly understood
molecular mechanisms [37]. Despite recent insights into
how lncRNAs function in such diverse cellular processes
as regulation of gene expression and assembly of cellular
structures, by and large, the key questions regarding
Figure 5 Effect of siRNA PCGEM1/PmiR-145 on cell migration. After 48 h, migrated and invasion cells were fixed, stained, and counted. siRNA
PCGEM1 and PmiR-145 significantly decreased LNCaP cell migration and invasion and have no effcets on RWPE-1 cell migration. A: a Transwell
migration assay was done on LNCaP cells with siRNA PCGEM1 and PmiR-145. P△* < 0.05 vs control and NC group. B: a Transwell migration assay was
done on LNCaP cells with siRNA PCGEM1 and PmiR-145. P△* > 0.05 vs control and NC group. C: a Transwell invasion assay was done on LNCaP cells
with siRNA PCGEM1 and PmiR-145. P△* < 0.05 vs control and NC group. D: a Transwell invasion assay was done on LNCaP cells with siRNA PCGEM1 and
PmiR-145. P△* > 0.05 vs control and NC group 1: Control group; 2: Negative group: 3: siRNA PCGEM1 group. 4. PmiR-145 group.
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lncRNA Prostate cancer gene expression marker 1
(PCGEM1) is overexpressed in PCa, suggesting roles in
proliferation, metastasis, and invasion [39]. In order to
reveal the mechanisms regulating expression in PCa, wehave predicted PCGEM1 interaction with miR-145 using
billogical information (Figure 1C), and futher investigated a
possible interaction with the tumor suppressor miR-145.
Co-transfection of LNCaP cells with miR-145 mimics or
miR-145 inhibitor with psiCHECK-2-PCGEM1 significantly
Figure 6 Effect of siRNA PCGEM1/pmiR-145 on prostate cancer xenografts. LNCaP tumor xenografts were established in male Athymic nude
mice. Animals in the treatment arm received siRNA PCGEM1 (500 nM /kg once daily) or pmiR-145 (16 μg/kg once daily). Control mice received
PBS (100 μl/kg once daily). Negative Control mice received empty plasmid or scrambled sequence (16 μg/kg once daily). After 20 daily
treatments, tumors injected with siRNA PCGEM1 or pmiR-145 were significant smaller than control or NC group tumors (P△* < 0.05).
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pressed reported gene expression when transfected with
empty psiCHECK-2 (Figure 1A, B). Thus, miR-145 may
regulate PCGEM1 expression by directly binding to target
sites within the PCGEM1 sequence.
We then demonstrated a mutual inhibitory control rela-
tionship between PCGEM1 and miR-145 by selective
siRNA-mediated PCGEM1 knockdown and miR-145 over-
expression. Expression of PCGEM1 (locus 2q32) was de-
tected in the androgen receptor-positive cell line LNCaP
but not in noncancerous prostate lines or androgen-
receptor negative Pca lines [23]. PCGEM1 overexpression
in LNCaP cells promotes cell proliferation and a dramatic
increase in colony formation, suggesting a role in cell
growth regulation [24]. In contrast, miR-145 expression
was low in all the prostate cell lines tested (PC3, LNCaP,
and DU145) compared to the normal cell line RWPE-1,
and in cancerous regions of human prostate tissue com-
pared to adjacent normal prostate tissue [39]. To test the
possibility of mutual negative regulation of PCGEM1 and
miR-145, we design a small interfering RNA targeting
PCGEM1 and a vector for miR-145 overexpression (pmiR-
145) and transfected these into LNCaP cells and normal
RWEP–1 cells. RT-PCR results showed that knockdown of
PCGEM1 in LNCaP cells increased miR-145 expression
(Figure 2A) and that miR-145 overexpression reduced
PCGEM1 expression (Figure 2B). Inhibition of PCGEM1
reduced LNCaP proliferation (Figure 3A), transwell migra-
tion and invasive capacity into Matrigel (Figures 5A, 6A),
and the growth of solid tumors, possibly by promoted early
apoptosis (Figure 4A). However, altering PCGEM1 expres-
sion had no significant effect on RWPE-1 cell growth, mi-
gration, or invasion (Figures 3, 4, 5, 6B). The proliferation,colony formation, and soft agar growth of liver cancer cells
was reduced by inhibiting expression of the lncRNA
TUC339 using an siRNA [40], while silencing HULC ex-
pression in hepatoma effectively inhibited the growth of
liver cancer cells [41]. In contrast, siRNA gene silencing of
MEG3 expression promote cell proliferation, whereas over-
expression inhibited proliferation and promoted apoptosis
[42]. Thus, individual lncRNAs can either promote or in-
hibit carcinogenesis. Selective knockdown and overexpres-
sion of lncRNAs may be feasible strategies to reduce
tumor growth in a variety of tissue. Specifically, miR-145 is
a well documented tumor suppressor [43-46], and we suc-
cessfully constructed an overexpressing vector that sup-
pressed PCa cell growth with no observable effects on
noncancerous prostate cells. Similarly, gain-of-function as-
says revealed that miR-145 transfection inhibited cell pro-
liferation, migration and invasion of PC3 and DU145 PCa
cell lines [47].
While PCGEM1 is known to be overexpressed in PCa,
it is unknown if overexpression directly causes hyperpro-
liferation and (or) metastasis [24]. Fu [48] found that
overexpression of PCGEM1 attenuated doxorubicin-
induced expression of p53 and p21Waf1/Cip1, and
inhibited apoptosis of LNCaP cells. Petrovics [24] re-
vealed that elevated PCGEM1 expression increased cell
proliferation and Rb phosphorylation. However, to the best
of our knowledge, no study has investigated PCGEM1
regulation by miR-145. An siRNA PCGEM1 inhibited
LNCaP cells growth and reduced migration and invasion,
likely by raising the expression levels of miR-145.
Indeed, we confirmed direct binding of miR-145 to the
PCGEM1 and demonstrated reciprocal regulation of these
two transcripts. Moreover, miR-145-mediated suppression
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cell proliferation and invasive capacity in vitro. In turn,
Reciprocal regulation of PCGEM1 and miR-145 promote
proliferation of LNCaP prostate cancer cells.
In conclusion, our study demonstrates reciprocal nega-
tive control of PCGEM1, a tumor-promoting long non-
coding RNA, and the tumor suppressor miR-145. This
study highlights the interrelationship between two clas-
ses of non-coding RNAs. Both downregulation of
PCGEM1 or overexpression of the miR-145 reduced the
proliferation and invasive capacity of prostate cancer
cells in vitro and in vivo.
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